In vivo tumor targeting imaging of cyclic RGD-modified heparin derivative to αvβ3-integrin expressing tumor

Journal of Pharmaceutical Investigation

Volumn 42, Issue 1, 2012, Pages 9-14

  Kim, Sung Eun ^a   Chin, Jungwook ^b   Lee, Hanna ^a   Byun, Youngro ^c   Park, Kyeongsoon ^d  

^a Korea University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Seoul National University   (South Korea)

^d Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

v 3 Integrin; Cyclic RGD; Heparin derivative; Optical imaging; Tumor targeting

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CYCLIC ARGINYLGLYCYLASPARTIC ACID HEPARIN DERIVATIVE; FLUORESCEIN; FLUORESCENT DYE; HEPARIN; LITHOCHOLIC ACID; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; GLIOMA; HUMAN; HUMAN CELL; IMAGING; MALE; MOUSE; NEAR INFRARED SPECTROSCOPY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SQUAMOUS CELL CARCINOMA;

EID: 84870324425     PISSN: 20935552     EISSN: 20936214     Source Type: Journal    
DOI: 10.1007/s40005-012-0003-x     Document Type: Article

References (18)

1. Brindle K (2008) New approaches for imaging tumour responses to treatment. Nat Rev Cancer 8: 94-107.
2. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-571.
3. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
4. Chen X, Conti PS, Moats RA (2004) In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res 64: 8009-8014.
5. Cheng Z, Wu Y, Xiong Z, Gambhir SS, Chen X (2005) Near-infrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjug Chem 16: 1433-1441.
6. Haubner RH, Wester HJ, Weber WA, Schwaiger M (2003) Radiotracer-based strategies to image angiogenesis. Q J Nucl Med 47: 189-199.
7. Hunter F, Xie J, Trimble C, Bur M, Li KC (2006) Rhodamine-RCA in vivo labeling guided laser capture microdissection of cancer functional angiogenic vessels in a murine squamous cell carcinoma mouse model. Mol Cancer 5: 5.
8. Kim JH, Kim YS, Park K, Kang E, Lee S, Nam HY, Kim K, Park JH, Chi DY, Park RW, Kim IS, Choi K, Chan Kwon I (2008) Self-assembled glycol chitosan nanoparticles for the sustained and prolonged delivery of antiangiogenic small peptide drugs in cancer therapy. Biomaterials 29: 1920-1930.
9. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392.
10. Park K, Kim K, Kwon IC, Kim SK, Lee S, Lee DY, Byun Y (2004) Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates. Langmuir 20: 11726-11731.
11. Park K, Lee GY, Kim YS, Yu M, Park RW, Kim IS, Kim SY, Byun Y (2006) Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Control Release 114: 300-306.
12. Park K, Ki Lee S, Hyun Son D, Ah Park S, Kim K, Won Chang H, Jeong EJ, Park RW, Kim IS, Chan Kwon I, Byun Y, Kim SY (2007a) The attenuation of experimental lung metastasis by a bile acid acylated-heparin derivative. Biomaterials 28: 2667-2676.
13. Park K, Kim JH, Nam YS, Lee S, Nam HY, Kim K, Park JH, Kim IS, Choi K, Kim SY, Kwon IC (2007b) Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles. J Control Release 122: 305-314.
14. Park K, Kim YS, Lee GY, Nam JO, Lee SK, Park RW, Kim SY, Kim IS, Byun Y (2007c) Antiangiogenic effect of bile acid acylated heparin derivative. Pharm Res 24: 176-185.
15. Park K, Kim YS, Lee GY, Park RW, Kim IS, Kim SY, Byun Y (2008) Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth. Pharm Res 25: 2786-2798.
16. Pasqualini R, Koivunen E, Ruoslahti E (1997) Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15: 542-546.
17. Yu MK, Lee DY, Kim YS, Park K, Park SA, Son DH, Lee GY, Nam JH, Kim SY, Kim IS, Park RW, Byun Y (2007) Antiangiogenic and apoptotic properties of a novel amphiphilic folate-heparin-lithocholate derivative having cellular internality for cancer therapy. Pharm Res 24: 705-714.
18. Zitzmann S, Ehemann V, Schwab M (2002) Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res 62: 5139-5143.